Long term effects of cilostazol in a dog with sick sinus syndrome

Kanno, Nobuyuki; Suzuki, Tomohiro

doi:10.1292/jvms.17-0018

Cited by 4 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have reported the effectiveness of orally administered cilostazol, a phosphodiesterase III inhibitor, in treating bradyarrhythmia in humans and animals [ 9 , 11 , 12 , 14 , 17 ]. Cilostazol is a platelet-aggregation inhibitor and has been administered intrinsically for preventing relapse in patients with cerebral infarction or chronic arterial occlusion.…”

mentioning

confidence: 99%

Effects of cilostazol on the heart rate in healthy dogs

Fukushima

Kawaguchi

Yamada

et al. 2018

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

Appropriate dosages of cilostazol have not been studied in veterinary patients, and the degrees of heart rate (HR) increase have not been studied in dogs administered cilostazol. Therefore, this study aimed to investigate the degrees of HR increase in healthy dogs administered cilostazol. Thirty healthy beagle dogs (15 males and 15 females; age, 5–8 years) were divided into 3 groups of 10 dogs each and orally administered 2.5, 5, or 10 mg/kg cilostazol (twice a day at 8:00 AM and 8:00 PM for 10 days). Higher HR increases were seen in the 5 mg/kg group than in the 2.5 mg/kg group at all time points except 7:00 AM, 9:00 AM, 1:00 PM, and 4:00 PM (P<0.01). Higher HR increases were also observed in the 10 mg/kg group than in the 2.5 mg/kg group at all time points except 4:00 PM (P<0.01). The 10 mg/kg group showed higher HR increases than the 5 mg/kg group at all time points except 6:00 AM, 7:00 AM, 6:00 PM, and 7:00 PM (P<0.05 for 4:00 PM and 5:00 PM; P<0.01 for the other time points). These results together show that the HR of healthy dogs increased in a dose-dependent manner after cilostazol administration twice a day at doses of 5 to 10 mg/kg. These results provide a useful basis for choosing cilostazol in the treatment of bradyarrhythmia in dogs.

show abstract

mentioning

confidence: 99%

Effects of cilostazol on the heart rate in healthy dogs

Fukushima

Kawaguchi

Yamada

et al. 2018

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

show abstract

“…The dosages and timing of administration of cilostazol were selected based on past case reports ( 12 , 13 ), basic research ( 21 ), and the experience of the attending veterinarian. The most frequently used dose of cilostazol was 10.0–10.9 mg/kg twice daily (20.0–21.8 mg/kg/day).…”

Section: Resultsmentioning

confidence: 99%

“…Cilostazol, a phosphodiesterase III inhibitor, has recently been reported to be effective in the treatment of bradyarrhythmia in both humans ( 8 – 11 ) and animals [SSS ( 12 , 13 )]. Cilostazol is a platelet aggregation inhibitor that is used in humans to prevent recurrence of cerebral infarction or chronic arterial occlusion.…”

Section: Introductionmentioning

confidence: 99%

“…One of the well-known side effects of cilostazol is tachycardia, which led to the use of this agent for bradyarrhythmia. In veterinary medicine, although there have been case reports of the effectiveness of cilostazol in dogs ( 12 , 13 ), there has been no large-scale study of its efficacy or the optimal dose. Thus, although cilostazol is used in dogs, the “standard dose” remains unknown at this time.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of cilostazol in canine bradyarrhythmia

et al. 2022

View full text Add to dashboard Cite

Recently, cilostazol, a phosphodiesterase III inhibitor, has been described as alternative medical treatment for canine bradyarrhythmia in cases for which pacemaker implantation was not indicated or available. In this retrospective study, we investigated the use and efficacy of cilostazol in dogs with bradyarrhythmia in Japan. Dogs that had been brought to the Tokyo University of Agriculture and Technology Animal Medical Center and 23 veterinary hospitals in Japan and been treated with cilostazol initially as the only therapeutic strategy for bradyarrhythmia between January 2010 and August 2021 were included in this study. Survival analyses were performed using Cox proportional hazards analysis, the log-rank test, and the generalized Wilcoxon test to evaluate the efficacy of cilostazol. Fifty-nine privately owned dogs were included in this study. In the survival time analysis, the risk of death was significantly lower and the survival rate was higher in cases in which cilostazol was administered at 10 mg/kg or more per dose. A third-degree atrioventricular block also significantly increased the risk of death and was associated with a lower survival rate. However, in some patients with a third-degree atrioventricular block, there was an increase in the ventricular rate and improvement in clinical symptoms without disappearance or decrease of the atrioventricular block. This study had several important findings that have not previously been reported concerning the use of cilostazol for canine bradyarrhythmia, including the appropriate dose in a clinical setting and the efficacy and prognosis according to the type of bradyarrhythmia.

show abstract

“…Although, cilostazol has been reported to increase the heart rate in healthy dogs, 15 and successfully treat sick sinus syndrome in a dog, the use of cilostazol has not been reported in cats. 16 The present study describes the clinical course and histological findings in a cat with high-grade AV block treated with cilostazol.…”

Section: Introductionmentioning

confidence: 93%

Long-term management of high-grade atrioventricular block using cilostazol in a cat

Iwasa

Nishii

Takashima

et al. 2019

Journal of Feline Medicine and Surgery Open Reports

View full text Add to dashboard Cite

Case summary A 12-year-old neutered female domestic shorthair cat was admitted for syncope. Clinical signs and electrocardiography revealed high-grade atrioventricular (AV) block. Treatment with cilostazol ameliorated the clinical signs and arrhythmia. However, the high-grade AV block recurred on several occasions. After 640 days, the cat presented again with clinical deterioration owing to reoccurrence of the arrhythmia and it died 11 days later. Histopathological examination revealed a loss of conduction cells within the His bundle. Relevance and novel information To our knowledge, this is the first report of high-grade AV block treated with cilostazol in a cat. Treatment with cilostazol prolonged survival for 650 days without pacemaker implantation. Histological findings suggested that the AV block was related to fibrosis of the impulse conduction system.

show abstract

Long term effects of cilostazol in a dog with sick sinus syndrome

Cited by 4 publications

References 14 publications

Effects of cilostazol on the heart rate in healthy dogs

Effects of cilostazol on the heart rate in healthy dogs

Efficacy of cilostazol in canine bradyarrhythmia

Long-term management of high-grade atrioventricular block using cilostazol in a cat

Contact Info

Product

Resources

About